<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04441073</url>
  </required_header>
  <id_info>
    <org_study_id>Lignocaine nebulization stress</org_study_id>
    <nct_id>NCT04441073</nct_id>
  </id_info>
  <brief_title>Lignocaine Nebulization for Attenuation of Intubation Stress Response</brief_title>
  <official_title>Lignocaine Nebulization for Attenuation of Intubation Stress Response in Patients With Severe Pre-eclampsia: a Prospective Double-blinded Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effect of lignocaine nebulization on attenuation of the pressor response during
      induction and emergence of anesthesia in patients with severe pre-eclampsia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pressor response to laryngoscopy and tracheal intubation is a very important issue in
      hypertensive pregnant patients that can lead to increased maternal intracranial pressure,
      cerebral haemorrhage, and cardiac failure with pulmonary oedema and may result in maternal
      mortality. The catecholamine release associated with laryngoscopy and intubation also causes
      uteroplacental vasoconstriction and adversely affect the neonate well-being.

      Therefore, the precise control of stress is necessary during general anesthesia in
      pre-eclamptic patients.Various drugs are used to suppress the pressor response including
      opioids, lidocaine, along with α and β adrenergic blockers.

      in this study the investigators will evaluate the effect of lignocaine nebulization on
      attenuation of the pressor response.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 24, 2020</start_date>
  <completion_date type="Anticipated">July 23, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 23, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic, diastolic, mean arterial blood pressure</measure>
    <time_frame>Preoperative-Intraoperative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Preoperative-Intraoperative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peripheral oxygen saturation</measure>
    <time_frame>Preoperative-Intraoperative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cough score during emergence</measure>
    <time_frame>Up to one hour after extubation</time_frame>
    <description>Grade of coughing (grade 0: no cough; grade 1: single cough with mild severity; grade 2: cough lasting less than 5 seconds with moderate severity; grade 3: more than 5 seconds of persistent cough)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>APGAR score</measure>
    <time_frame>One, 5 and 10 minutes after delivery of the fetus</time_frame>
    <description>APGAR stands for &quot;Appearance, Pulse, Grimace, Activity, and Respiration.&quot;
In the test, five things are used to check a baby's health. Each is scored on a scale of 0 to 2, with 2 being the best score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sore throat and hoarseness of voice</measure>
    <time_frame>Postoperative (one, 6 and 24 hours)</time_frame>
    <description>The incidences and severities of postoperative sore throat and hoarseness of voice will be measured using direct questions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pressor Response</condition>
  <arm_group>
    <arm_group_label>Lignocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>preoperative nebulization of lignocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>preoperative nebulization of normal saline (Nacl 0.9%) as a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lignocaine</intervention_name>
    <description>preoperative nebulization of lignocaine</description>
    <arm_group_label>Lignocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>preoperative nebulization of normal saline (Nacl 0.9%) as a placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal saline (Nacl 0.9%)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologist (ASA) II , III with severe pre-eclampsia

          -  Scheduled for caesarean deliveries under general anesthesia

        Exclusion Criteria:

          -  severe obesity (BMI ≥ 40 )

          -  Cardiac patients

          -  History of diabetes

          -  Renal dysfunction (Elevated creatinine ≥ 2 mg\dl)

          -  Hepatic dysfunction (Elevated hepatic enzymes three times above normal value)

          -  Known fetal anomalies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fatma N. Mohamed, M.D.</last_name>
    <phone>+201003633992</phone>
    <email>fatmanabil2012@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alaa A. Gharib, M.B.B.Ch.</last_name>
    <email>lola.gh2022@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assiut University</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Fatma N. Mohamed, M.D.</last_name>
      <phone>+201003633992</phone>
      <email>fatmanabil2012@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Alaa Gharib</last_name>
      <email>lola.gh2022@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 5, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>FATMA NABIL AHMED MOHAMED</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pressor response</keyword>
  <keyword>pre-eclampsia</keyword>
  <keyword>Lignocaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

